Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare disease comprising <3% of extranodal lymphomas. It frequently reveals an activated B-cell (ABC)-like phenotype. ABC-like DLBCL was reported to have gainof-function mutations in MYD88, CD79B, CARD11, and TNFAIP3, resulting in constitutive activation of the NFkB pathway. Because of the rare occurrence of PB-DLBCL, the frequency of MYD88 and CD79B mutations is still unknown. We used Sanger sequencing to study these mutations from 46 breast DLBCL cases and also investigated the associated clinicopathologic factors. MYD88 L265P was confirmed by allelespecific polymerase chain reaction and compared with the Sanger sequencing results. MYD88 L265P and CD79B mutations were detected in 27/46 (58.7%) and 11/33 (33.3%) cases, respectively. Twenty-eight of 46 cases met the criteria for PB-DLBCL, and the latter 18 cases were further classified as clinical breast DLBCL (CLB-DLBCL). The frequency of MYD88 L265P and CD79B mutations was 16/28 (57.1%) and 9/23 (39.1%), respectively, in PB-DLBCL and 11/18 (61.1%) and 2/ 10 (20%), respectively, in CLB-DLBCL. When the cutoff value was set at DCtr1, the result of allele-specific polymerase chain reaction for MYD88 corresponded to those of the Sanger sequence at 92.6% sensitivity and 100% specificity. According to Choi's algorithm, 16/27 (59.3%) demonstrated an ABC-like phenotype in PB-DLBCL, and 15/18 (83.3%) demonstrated an ABC-like phenotype in CLB-DLBCL. In conclusion, MYD88 L265P and CD79B mutations were frequently detected in PB-DLBCL, and they may be key molecules associated with PB-DLBCL lymphomagenesis. Further analysis will be required to clarify the mechanism of its pathogenesis.
P rimary breast diffuse large B-cell lymphoma (PB-DLBCL) is a rare disease comprising approximately 1% of non-Hodgkin's lymphomas and approximately 3% of extranodal lymphomas. 1 Although the 5-year overall survival (OS) was reported to be 63% in the prerituximab era, it improved to 87% with the introduction of rituximab. 2, 3 Involvement of the central nervous system (CNS) is rather frequent (11.5% to 13.3%) and can sometimes be fatal to patients in PB-DLBCL. 4, 5 Activated B-cell (ABC)-like DLBCL is characterized by the constitutive activation of the NFkB pathway. Gene mutations in this pathway, such as in MYD88, CD79B, CARD11, and TNFAIP3 (A20), were reported in ABC-like DLBCL and were considered to be responsible for the lymphomagenesis. [6] [7] [8] It was reported that 77% to 95% of PB-DLBCL cases demonstrated an ABC-like phenotype. 9, 10 Myeloid differentiation factor 88 (MYD88) is an adaptor molecule for Toll-like receptor and interleukin-1 receptor signaling. MYD88 L265P was reported to be frequently identified in ABC-like DLBCL (21.6% to 31.2%) compared with the germinal center B-cell (GCB)-like DLBCL (6% to 9.7% 6, 8, 11 ). MYD88 L265P was the most frequently found MYD88 mutation. It was demonstrated to be a gain-of-function mutation, which activates the NFkB pathway, resulting in tumor cell survival. 6 CD79B is a subunit of the B-cell receptor and has an immunoreceptor tyrosine-based activation motif (ITAM). It is upstream of the NFkB pathway. 12 Similar to MYD88 L265P, the CD79B mutation was frequent in ABC-like DLBCL (18% to 23%) rather than in GCB-like DLBCL (1.6% to 5.1% 6, 8, 13 ). The CD79B mutation was frequently identified in the first tyrosine (Y196) of ITAM and was also demonstrated to be a gain-of-function mutation involved in activating the NFkB pathway. 12, 13 Because of the high frequency of the ABC-like phenotype, significant cases of PB-DLBCL were suspected to have MYD88 L265P and CD79B mutations. However, to the best of our knowledge, because of its rare occurrence, there has been no mutation analysis. We performed a mutation analysis of MYD88 L265P and CD79B for PB-DLBCL and also analyzed the possible associations with clinicopathologic factors.
MATERIALS AND METHODS

Patient Selection
A total of 46 cases of DLBCL of the breast were investigated. Sixteen cases were from the pathology database at our institution, and 30 cases were from our collaborating hospitals (4 cases from Hiroshima City Hospital, 4 from Kagawa Rosai Hospital, 7 from Nagoya University Hospital, 5 from Fukushima Medical University, and 10 from Chi-Mei Medical Center). Diagnosis was made according to the current WHO classification. 14 Clinical information was available for 41 cases. All CD5positive cases did not have a history of prior or subsequent chronic lymphocytic leukemia/small lymphocytic lymphoma. We defined PB-DLBCL as lymphoma restricted to the mammary glands and ipsilateral axillary lymph nodes and without a history of prior lymphoma according to previously described criteria. 1 Twenty-eight cases met these criteria (patients 1 to 28), and we analyzed them separately as shown in Tables 1-3 . The other 18 cases (patients 29 to 46) did not meet these criteria but had the main lesions in the breast and were managed as breast DLBCL; we named this group "clinical breast DLBCL (CLB-DLBCL)". In the CLB-DLBCL group, 5 cases had extranodal site involvement other than the breast. Patient 29 had involvement in the ovary, patient 31 had CNS involvement, patients 32 and 36 had bone marrow involvement, and patient 40 had bone marrow and spleen involvement. The study protocol was conducted with the approval of the Institutional Review Board at Okayama University. All study procedures were conducted in accordance with the guidelines of the Declaration of Helsinki.
DNA Extraction and Polymerase Chain Reaction
DNA was extracted from 10% formalin-fixed paraffin-embedded tissue using the Qiagen DNeasy kit (Qiagen, Venlo, the Netherland) according to the manufacturer's instructions. All cases except patient 18 had a tumor percentage >20%. Sequences of primers for MYD88 and CD79B exon 5 are listed in Supplementary  Table 1 (Supplemental Digital Content 1, http://links. lww.com/PAS/A333).
MYD88 was amplified by seminested polymerase chain reaction (PCR) using AmpliTaq Gold PCR Master MIX (Applied Biosystems, California). The first PCR condition was 10 minutes at 951C, followed by 35 cycles of 951C for 1 minute, 601C for 1 minute, 721C for 1 minute, and for 5 minutes at 721C after the last cycle. The second PCR condition was 10 minutes at 951C followed by 30 cycles of 951C for 1 minute, 601C for 1 minute, 721C for 1 minute, and for 10 minutes at 721C after the last cycle.
ITAM of CD79B exon 5 was amplified by PCR using KOD FX (Toyobo, Osaka, Japan). The PCR conditions were 10 minutes at 941C followed by 30 to 40 cycles of 941C for 45 seconds, 601C for 1 minute, 721C for 1 minute, and 10 minutes at 721C after the last cycle.
Sanger Sequencing
PCR products were purified using ExoSap (Affymetrix/USB product, California) and were sequenced in both directions using the BigDye Terminator version 3.1 cycle Sequencing Kit (Applied Biosystems) following the manufacturer's instructions. The purified samples were analyzed on an Applied Biosystems 3130xl Genetic Analyzer (Applied Biosystems) according to the manufacturer's instructions. 
Allele-specific PCR
Immunohistochemistry and In Situ Hybridization
We performed immunohistochemical (IHC) analysis on 10% formalin-fixed paraffin-embedded tissue sections using Bond-Max Autostainer (Leica Biosystems, Melbourne, Australia) following the manufacturer's instructions. The information regarding the primary antibodies is documented in Supplementary Table 2 (Supplemental Digital Content 1, http://links.lww.com/ PAS/A333). The cutoff values were set at different percentages as follows: 80% for GCET1 and FOXP1 and 30% for MUM1, BCL6, CD10, and BCL2. Three expert hematopathologists (K.T., T.M.-T., and T.Y.) evaluated all the slides, and the cutoff value of c-MYC was set at 70%. 15, 16 We classified ABC-like and GCB-like DLBCL according to Choi's algorithm. 15 The Ki-67-labeling index was counted at 3 high-power field (Â 400), and the average was then calculated. In situ hybridization (ISH) for Epstein-Barr virus-encoded small RNA 1 (EBER-1) probes (PB0589, Leica Biosystems, Newcastle Upon Tyne, UK) was used to detect Epstein-Barr virus.
Fluorescence In Situ Hybridization of MYC, BCL2, and BCL6
Fluorescence in situ hybridization (FISH) for BCL6 translocation was performed for immunohistochemically BCL6-positive cases using Vysis LSI BCL6 (ABR) Dual Color, Break Apart Rearrangement Probe (Abbott Molecular, Wiesbaden Dlkenheim, Germany) according to the manufacturer's instructions. In brief, hybridization was performed for 48 hours at 371C using an incubator after denaturation at 731C for 3 minutes using a Hybridizer (Dako, Glostrup, Denmark). To detect MYC and BCL2 translocation, IQ-FISH assay was performed using Agilent FISH General Purpose Reagents (Agilent, Santa Clara) according to the manufacturers' instructions. Several probes were used as follows: (1) MYC (Sure FISH Statistical Analysis w 2 and Fisher exact tests were performed using Statcel3 (The Publisher OMS Ltd, Saitama, Japan). Survival curves were generated by the Kaplan-Meier method with the log-rank test using SPSS, version 14.0 J (IBM, Armonk). P < 0.05 was considered statistically significant.
RESULTS
Patients' Characteristics, Histopathology, and IHC Features of Breast DLBCL
Patients' characteristics are summarized in Supplementary Table 3 (Supplemental Digital Content 1, http:// links.lww.com/PAS/A333). Among all 46 breast DLBCL cases, 28 cases met the criteria for PB-DLBCL, as described in the Materials and methods section, and the latter 18 cases were further classified as CLB-DLBCL. Follow-up data were obtained from 43 cases, and the median follow-up time was 30.8 (0.97 to 173.8) months. All patients were female, and the average age was 62.8 (30 to 87) years. Four of the 28 cases of PB-DLBCL had a tumor size >5 cm. One case of PB-DLBCL presented with CNS involvement at the time of recurrence. Three of the PB-DLBCL cases had involvement of the opposite breast, which included 2 cases at the time of diagnosis and 1 case at the time of recurrence. Eight of the 28 cases demonstrated an elevation in serum lactate dehydrogenase levels. In 1 of the 15 cases, soluble interleukin-2 receptor was >1000 U/mL. Therapy information on 26 of 28 cases was available: (1) 2 patients underwent only surgical resection; (2) 10 patients underwent surgical resection and chemotherapy (rituximab combination therapy for 5 cases); (3) 1 patient underwent surgical resection and chemoradiation therapy (rituximab combination therapy); (4) 9 patients underwent only chemotherapy (rituximab combination therapy for all cases); and (5) 4 patients underwent chemoradiation therapy (rituximab combination therapy for all cases). The IHC results and classification by Choi's algorithm are listed in Table 1 and Figure 1 . In PB-DLBCL, according to Choi Figure 2F . Within these 28 PB-DLBCL cases, the frequency of MYD88 L265P and CD79B mutations was 16/28 (57.1%) and 9/23 (39.1%), respectively; within 18 CLB-DLBCL cases, the frequency of MYD88 L265P and CD79B mutations was 11/18 (61.1%) and 2/10 (20%), respectively.
Clinicopathologic Significance of MYD88 L265P and CD79B Mutations and Immunophenotyping of c-MYC and BCL2
Associations between clinicopathologic factors and mutation statuses of MYD88 and CD79B are summarized in Table 3 . No factors significantly correlated with MYD88 L265P or CD79B nonsynonymous mutations. However, cases with MYD88 L265P had the tendency to be CD5 negative and have tumor sizes >5 cm, whereas cases with the CD79B nonsynonymous mutation had a tendency to be MUM1 positive and have a Ki-67-labeling index of >40%. The OS and progression-free survival (PFS) results of PB-DLBCL are shown in Table 4 , Figure 3 . There was no significant difference in OS or PFS according to the presence of MYD88 L265P (OS, P = 0.937 and PFS, P = 0.642). C-MYC, BCL2, and c-MYC/BCL2 coexpression was not a significant prognostic factor (OS, P = 0.655, 0.351 and PFS, P = 0.351, 0.351, respectively). The OS and PFS curves for all cases (PB-DLBCL and CLB-DLBCL) are shown in Supplementary Figure 1 respectively); however, there was no significant difference in OS (P = 0.985 and 0.909, respectively).
FISH of MYC, BCL2, and BCL6
We performed BCL6 FISH analysis in immunohistochemically positive cases. Five of 21 cases revealed BCL6 translocation; these 5 cases were CLB-DLBCL (Table 1 and Fig. 1X ). No case harbored MYC or BCL2 translocation. Two cases (patients 26 and 39) had BCL2 gene amplification ( Supplementary Fig. 2 , Supplemental Digital Content 1, http://links.lww.com/PAS/ A333). 
DISCUSSION
Recent reports have highlighted the significance of MYD88 L265P and CD79B mutations as key players in the constitutive activation of the NFkB pathway in lymphomagenesis. These mutations were frequently detected in ABC-like DLBCL (21.6% to 29% and 18% to 23%, respectively), and they were frequently detected in extranodal DLBCL, which is the predominant site of the ABC-like phenotype, such as CNS and testes. [6] [7] [8] 11, 13, [17] [18] [19] [20] [21] Although there were few molecular genetic data regarding PB-DLBCL because of its rare occurrence, PB-DLBCL was considered to have MYD88 L265P and CD79B mutations as it frequently exhibited an ABC-like phenotype.
In this study, MYD88 L265P and CD79B mutations were frequently identified in 58.7% and 33.3% of all breast DLBCL cases, respectively. When confined to 28 PB-DLBCL cases, the frequency of MYD88 L265P (57.1%) and CD79B mutations (39.1%) occurred. There was no BCL2, BCL6, or MYC translocation in PB-DLBCL. All 5 cases that had BCL6 translocation were included in CLB-DLBCL. Besides, all cases were negative for EBER ISH. These results suggested that MYD88 L265P and CD79B mutations may be involved in the initial stages of PB-DLBCL lymphomagenesis. These aberrations were frequently observed in immunoprivileged lymphoma sites, such as the CNS and testes (sites that tolerate antigen stimulation); this suggests that they were associated with the initial stage of lymphomagenesis. The frequency of CD5 positivity was higher in this series than in previous reports. In this series, it was 25.9% in PB-DLBCL (Table 1) . No patient had a history of prior or subsequent chronic lymphocytic leukemia/small lymphocytic lymphoma; therefore, these cases were considered to be de novo CD5-positive DLBCL. The survival rate was the same as in previous studies, and CD5 positivity was not an adverse factor in p65-NFkB to the nucleus, resulting in the immortalization of the tumor cells. 6, 12 Fernandez-Rodriguez et al 11 reported that MYD88 L265P was an independent prognostic factor for DLBCL; however, in their report, both nodal and extranodal cases were included, and respective analyses were not performed. Another study reported that MYD88 L265P was unrelated to the prognosis; however, MYD88 protein expression evaluated by immunostaining did affect the prognosis. There has been little agreement regarding MYD88 L265P as a prognostic factor. 13, 18 In this study, 28 cases met the conventional criteria of PB-DLBCL. Eighteen other cases were classified as CLB-DLBCL: 5 cases had extranodal sites (ovary, CNS, bone marrow, and spleen), and 13 cases had lymph node involvement other than ipsilateral axillary lymph node. We separately analyzed these 2 groups; however, there was no significant difference regarding the frequency of MYD88 L265P (57.1% vs. 61.1%). Furthermore, similar to PB-DLBCL, 83.3% (15/18) of CLB-DLBCL cases were classified as ABC-like DLBCL. We believed that CLB-DLBCL may have some characteristics similar to those of PB-DLBCL.
Although MYD88 L265P and CD79B mutations may not be prognostic factors in breast DLBCL, tumors holding these mutations could be the targets of molecular-targeted drugs. In Waldensto¨m macroglobulinemia, it was reported that MYD88 L265P activated Bruton tyrosine kinase (BTK), thus contributing to the survival of tumor cells, and BTK inhibitor contributed to the regression of tumor growth. [22] [23] [24] Protein kinase C (PKC) was involved with the activation of the NFkB pathway through CD79B mutation. In vitro tumor cells with CD79B mutation were reported to be sensitive to PKC inhibitors. 12, 25 Thus, BTK and PKC inhibitors may be the choices of treatment for PB-DLBCL, which has a high frequency of MYD88 L265P and CD79B mutations.
As for the cutoff value of AS-PCR, we set it at DCtr1 in this study. Under these conditions, the results of AS-PCR corresponded to those of Sanger sequencing at high sensitivity and specificity. In 1 previous report, the cutoff value was set at DCt < 10; however, they used the TaqMan AS custom probe kit under different reaction conditions with a different thermal cycler machine than that used in this study. Therefore, we could not accurately compare the cutoff value. 26 In either situation, AS-PCR was considered to be useful for detecting MYD88 L265P.
It was reported that DLBCL with c-MYC expression had poor OS, and DLBCL with c-MYC coexpressed with BCL2 had even worse OS and PFS. 16, 27 In this study, in the univariate analysis, all DLBCL cases (PB-DLBCL and CLB-DLBCL) with c-MYC expression revealed a poorer PFS than did cases without c-MYC expression, and cases with c-MYC coexpressed with BCL2 demonstrated a worse PFS than did cases without c-MYC or BCL2 ( Supplementary Fig. 1 , Supplemental Digital Content 1, http://links.lww.com/PAS/A333), although there were no significant differences in multivariate analysis. Many previous reports set the cutoff value at 40% to 50% for c-MYC positivity 16, 27 ; however, in this study, we adopted 70% as the cutoff value because cases with >70% positivity demonstrated strong and uniform positivity. This cutoff value provided high interobserver reproducibility. Moreover, we analyzed in the setting that the cutoff value at 40% or 50%; however, both expression statuses did not correlate with OS or PFS (data not shown).
In conclusion, we demonstrated that MYD88 L265P and CD79B mutations were frequently detected in PB-DLBCL and suggested that these mutations may be important for DLBCL-associated lymphoma development. Further molecular and pathologic analyses should be conducted to elucidate the mechanism of the pathogenesis of PB-DLBCL.
